Drug Trial Radar · NCT00997997
Avelox in Complicated Skin and Skin Structure Infections
Last checked: Nov 19, 2026Latest source record: Nov 16, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,127
Actual
Start
Oct 2005
Primary completion
Dec 2008
Study completion Dec 2008
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Oct 20, 2009
Design
- Study type
- Observational
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This international, prospective, non-interventional, non-controlled observational study obtains data on efficacy, safety and tolerability of Avelox treatment under daily-life treatment conditions. Specifically investigated are the improvement of clinical symptoms and the duration until infection improvement and cure.Any patient with a diagnosis of complicated skin and skin structure infection (cSSSI) treated with Avelox can be documented. The observation period for each subject covers the treatment period with Avelox. For each patient, the physician documents data at an initial visit and one or two follow-up visit(s) in line with routine practice.
Conditions
- Skin Diseases, Bacterial
Interventions
Moxifloxacin (Avelox, BAY12-8039)Drug
400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy: course of severity of infection, course of clinical signs and symptoms, duration until improvement, duration until recovery, duration until wound closure, overall assessment of efficacy by the physician, reuse of AveloxTime frame: last documented follow-up visit, according to the respective praxis routine
Locations
12 sites in 12 countries. Site status is shown where the registry gives one.
Site not named
Many Locations, Austria
Site not named
Many Locations, Bulgaria
Site not named
Many Locations, Egypt
Site not named
Many Locations, Germany
Site not named
Many Locations, Greece
Site not named
Many Locations, Indonesia
Site not named
Many Locations, Pakistan
Site not named
Many Locations, Philippines
Site not named
Many Locations, Saudi Arabia
Site not named
Many Locations, Slovenia
Site not named
Many Locations, South Korea
Site not named
Many Locations, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.